ClinicalTrials.Veeva

Find clinical trials for Pancreatic Cancer in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Adenocarcinoma
Cancer
Carcinoma
Colorectal Cancer
Lung Cancer
Non-Small-Cell Lung Carcinoma
Squamous Cell Carcinoma of Head and Neck

Pancreatic Cancer trials near Montréal, QC, CAN:

Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer...

Enrolling
Metastatic Pancreatic Cancer
Pancreatic Adenocarcinoma
Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Alpha Tau Medical

Montréal, Quebec, Canada and 1 other location

Salmonella Typhimurium expressing IL-2, in patients with metastatic pancreatic cancer on standard chemotherapy (either FOLFIRINOX o ...

Active, not recruiting
Metastatic Pancreatic Cancer
Drug: Gemcitabine/Abraxane Alone (Historical Controls)
Drug: FOLFIRINOX Alone (Historical Controls)

Phase 2

Salspera

Montreal, Quebec, Canada

with either gemcitabine plus nab-paclitaxel (G/NP) or FOLFIRINOX in the treatment of participants with locally advanced, unresectable pancreatic...

Active, not recruiting
Pancreatic Cancer Non-resectable
Drug: Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX
Drug: Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX

Phase 3

FibroGen
FibroGen

Montreal, Quebec, Canada and 89 other locations

of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid ...

Enrolling
Gastroesophageal Junction Cancer
Gastric Cancer
Drug: l-leucovorin
Drug: Gemcitabine

Phase 2

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 46 other locations

given to participants. Part C will use the information from Parts A and B to see if SGN-BB228 is safe and if it works to treat solid tumor cancers...

Enrolling
Non-small Cell Lung Cancer
Pancreatic Neoplasms
Drug: SGN-BB228

Phase 1

Seagen
Seagen

Montreal, Quebec, Canada and 17 other locations

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer age...

Enrolling
Breast Cancer
Biliary Cancer
Drug: Camizestrant
Drug: Paclitaxel

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 71 other locations

and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers...

Active, not recruiting
Neoplasms Pancreatic
Pancreatic Adenocarcinoma
Drug: Gemcitabine - 21 day cycle
Drug: Lomustine

Phase 2

Actuate Therapeutics

Montréal, Quebec, Canada and 65 other locations

The primary purpose of this study is to find the recommended dose of LGK974 as a single agent and in combination with PDR001 that can be safely given...

Active, not recruiting
BRAF Mutant Colorectal Cancer
Lung Squamous Cell Cancer
Drug: LGK974
Biological: PDR001

Phase 1

Novartis
Novartis

Montreal, Quebec, Canada and 19 other locations

BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially d...

Active, not recruiting
Gastric Cancers
Pancreatic Cancer
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)
Drug: BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion)

Phase 1, Phase 2

Bold Therapeutics

Montréal, Quebec, Canada and 12 other locations

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8...

Enrolling
Advanced Solid Tumor
Drug: CX-5461

Phase 1

Senhwa Biosciences

Montréal, Quebec, Canada and 7 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems